EOHILIA™ (budesonide oral suspension) is an FDA approved 12-week oral treatment for EoE in people 11 years and older. It has not been shown to be safe and effective for longer than 12 weeks. Website …

Nov 26, 2025 · Eohilia (budesonide) suspension is used to treat eosinophilic esophagitis (EoE), to reduce symptoms and improve the ability to swallow. Includes dose, side effects, interactions ,and more

Mar 7, 2025 · How Was Eohilia Studied for the Treatment of EoE? Eohilia was studied in two clinical trials involving people aged 11 and older who have EoE.

Indication and Limitations of Use EOHILIA (budesonide oral suspension) is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

Feb 12, 2024 · FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

Mar 17, 2025 · Historically, treatment options for EoE have been limited, often relying on proton pump inhibitors (PPIs), dietary modifications, and off-label use of medications such as corticosteroids. 1 …

EOHILIA is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). (1)

EOHILIA is the first and only 12-week, FDA-approved oral treatment designed for people with eosinophilic esophagitis (EoE) 11 years and older. It is a liquid-like form of budesonide specifically …

Nov 26, 2025 · Eohilia is FDA-approved for a specific 12-week treatment course of eosinophilic esophagitis (EoE). Learn why you take Eohilia for a limited time and the safety considerations after …

Numan L, Kalot MA, Brotherton T, Tarakji A, Hamdeh S. Comparison of viscous budesonide and fluticasone in the treatment of patients with eosinophilic esophagitis: a systematic review and meta …